RETRACTED ARTICLE

JNK confers 5-fluorouracil resistance in p53-deficient and mutant p53-expressing colon cancer cells by inducing survival autophagy

Xinbing Sui[1,2]*, Na Kong[1,2]*, Xian Wang[1,2], Yong Fang[1], Xiaotong Hu[1,2], Yinghua Xu[1], Wei Chen[1], Kaifeng Wang[1], Da Li[1], Wei Jin[1], Fang Lou[1], Yu Zheng[1], Hong Hu[1], Liu Gong[1], Xiaoyun Zhou[1], Hongming Pan[1,2] & Weidong Han[1,2]

[1]Department of Medical Oncology, Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, China, [2]Biomedical Research Center and Key Laboratory of Biotherapy of Zhejiang Province, Hangzhou, China 310016.

Correspondence and requests for materials should be addressed to H.M.P. (drpanhm@aliyun.com) or W.D.H. (weidong2011@163.com)

* These authors contributed equally to this work.

Deficiency or mutation in the p53 tumor suppressor gene commonly occurs in human cancer and can contribute to disease progression and chemotherapy resistance. Currently, although the pro-survival or pro-death effect of autophagy remains a controversial issue, increasing data seem to support the idea that autophagy facilitates cancer cell resistance to chemotherapy treatment. Here we report that 5-FU treatment causes aberrant autophagosome accumulation in HCT116 p53$^{-/-}$ and HT-29 cancer cells. Specific inhibition of autophagy by 3-MA, CQ or small interfering RNA treatment targeting Atg5 or Beclin 1 can potentiate the re-sensitization of these resistant cancer cells to 5-FU. In further analysis, we show that JNK activation and phosphorylation of Bcl-2 are key determinants in 5-FU-induced autophagy. Inhibition of JNK by the compound SP600125 or JNK siRNA suppressed autophagy and phosphorylation of c-Jun and Bcl-2 but increased 5-FU-induced apoptosis in both HCT116 p53$^{-/-}$ and HT29 cells. Taken together, our results suggest that JNK activation confers 5-FU resistance in HCT116 p53$^{-/-}$ and HT29 cells by promoting autophagy as a pro-survival effect, likely via inducing Bcl-2 phosphorylation. These results provide a promising strategy to improve the efficacy of 5-FU-based chemotherapy for colorectal cancer patients harboring a p53 gene mutation.

olorectal cancer (CRC) is still the third most common cancer and the second most common cause of cancer-related death worldwide, although considerable progress has been made in the treatment of CRC in recent years[1,2]. Thus far, 5-fluorouracil (5-FU) remains a widely used chemotherapeutic drug in the treatment of various cancers, including colorectal carcinoma, breast cancer, gastric cancer and other solid tumors. The anticancer efficacy of 5-FU is considered to be partly attributed to its ability to induce p53-dependent cell growth arrest and apoptosis; consequently, mutations or deletions of p53 can cause cells to become resistant to 5-FU[3–5]. Therefore, how to overcome 5-FU resistance caused by mutations or deletions of p53 will be a key issue for the design of more effective individualized therapeutic strategies.

Autophagy is an evolutionarily conserved catabolic process in which cellular contents are delivered to lysosomes for degradation[6]. Autophagy is regulated by a family of autophagy-related (ATG) genes, and it can have either a beneficial or detrimental cellular effect depending on the response to environmental stressors[7]. Autophagy is believed to have an important role in tumor development. It has been suggested that autophagy allows cells to recycle long-lived proteins and dysfunctional organelles, thus providing metabolites and ATP levels that are utilized for cell survival when faced with with diverse environmental stressors such as nutrient starvation, endoplasmic reticulum stress, hypoxia or treatment with chemotherapeutic agents[8]. Paradoxically, in some cases, autophagy can also contribute to autophagic cell death, a form involving cell degradation via the actions of lysosomes (a distinct form of cell death in contrast to type I programmed cell death or apoptosis)[9]. Although the paradoxical dual effect possible for autophagy in cancer cell fate remains controversial, overwhelming evidence supports the hypothesis that autophagy is an important resistance mechanism to chemotherapy in multiple malignancies[10–12].

Figure 1 | Autophagy is activated in a time-dependent manner in 5-FU-treated HCT116 p53$^{-/-}$ and HT-29 cells. (A) The cell viability of colon cancer cells was measured via the MTT assay after 5-FU treatment. The experiments were performed in triplicate. (B) The conversion from LC3-I to LC3-II, as well as p62 and active caspase-3 expression, was detected by western blotting (the blots were cropped, and the full-length blots are included in the supplementary information).

c-Jun N-terminal kinase (JNK) plays a critical role in the outcome and sensitivity to anticancer therapies. Activated JNK can transmit extracellular signals to regulate cell proliferation, apoptosis and autophagy in response to chemotherapeutic agents[13,14]. The JNK signaling pathway has been shown to be closely associated with the resistance to several antitumor agents such as cisplatin, mitoxantrone, docetaxel and oxaliplatin[15-18]. However, no relationship has been reported between 5-FU resistance caused by mutations or deletions of p53 and the JNK signaling pathway.

We investigated the impact of autophagy regulation and JNK signaling on 5-FU resistance in p53-deficient HCT116 cancer cells (HCT116 p53$^{-/-}$) and p53-mutant HT-29 cancer cells. Here we demonstrate that autophagy is activated by 5-FU treatment in HCT116 p53$^{-/-}$ and HT29 cells. Moreover, JNK activation and Bcl-2 phosphorylation have been proven to trigger survival-promoting autophagy to protect tumor cells against the cytotoxic effects of 5-FU. Specific inhibition of autophagy or JNK can potentiate the re-sensitization of these resistant cancer cells to 5-FU and significantly enhance 5-FU-induced apoptosis, implying that JNK activation confers 5-FU resistance in HCT116 p53$^{-/-}$ and HT29 cells by inducing survival autophagy.

Results

5-FU treatment in human colon cells. Thus far, 5-FU remains a widely used chemotherapeutic drug in clinical colon cancer therapy.

To examine its effect on human colon cells, we used RKO (wt p53), HT-29 (mutant p53), HCT116, and wt p53 HCT116 (HCT116 p53$^{+/+}$) cell lines and their isogenic derivatives, in which the p53 gene had been somatically knocked out (HCT116 p53$^{-/-}$). After treatment with various concentrations of 5-FU for 24 h, MTT assay results showed that HCT116 p53$^{+/+}$ and RKO cells were hypersensitive to 5-FU treatment, but very few dying cells emerged in HCT116 p53$^{-/-}$ and HT-29 cells after 5-FU treatment, indicating that HCT116 p53$^{-/-}$ and HT-29 cells may be insensitive or resistant to 5-FU (Figure 1a). Consequently, we used 20 μM 5-FU in HCT116 cells and 30 μM 5-FU in RKO and HT-29 cells for 24 h in subsequent experiments.

Aberrant autophagosome accumulation is involved in p53-deficient and mutant p53-expressing colon cancer cells. To examine whether autophagy is an important mechanism for 5-FU resistance in p53-deficient and mutant p53-expressing colon cancer cells, we compared HCT116 p53$^{+/+}$, HCT116 p53$^{-/-}$, RKO and HT-29 cell lines. Interestingly, the results suggested that functional autophagy was activated in HCT116 p53$^{-/-}$ and HT-29 cells because an increased LC3-II/I ratio and decreased abundance of the autophagic degradation marker p62 were induced in a time-dependent manner in 5-FU-treated HCT116 p53$^{-/-}$ and HT-29 cells but not in HCT116 p53$^{+/+}$ and RKO cells (Figure 1b). By contrast, the apoptotic protein caspase-3 increased in a time-dependent manner in 5-FU-treated HCT116 p53$^{+/+}$ and RKO cells but not in HCT116 p53$^{-/-}$ and HT-29 cells,

Figure 2 | Electron microscopy shows ultrastructures of autophagosome in these cells. The experiments were performed in triplicate. Bar = 1 μm.

indicating that autophagy may protect HCT116 p53⁻/⁻ and HT-29 cells against cell death induced by 5-FU treatment. Next, to confirm the induction of autophagy, all of these cells were analyzed by electron microscopy. After HCT116 p53⁺/⁺ and RKO cells were treated with 5-FU for 24 h, very few autophagosomes were observed in most cells (Figure 2). By contrast, most of the HCT116 p53⁻/⁻ and HT-29 cells displayed extensive accumulation of double and multimembraned structures with a broad range of morphologies. These results imply that induction of autophagy may be a key mediator for the resistance to 5-FU in HCT116 p53⁻/⁻ and HT-29 cells.

Autophagy promotes resistance against 5-FU-induced cell death in HCT116 p53⁻/⁻ and HT-29 cells. To assess whether autophagy contributed to the resistance to 5-FU in HCT116 p53⁻/⁻ and HT-29 cells, we first treated these cells with two pharmacological inhibitors of autophagy, 3-methyladenine (3-MA) and chloroquine (CQ). 3-MA, a class III phosphatidylinositol 3-kinase (PtdIns3K) inhibitor, can block the early steps of autophagy[19]. CQ is a lysosomotropic agent that acts as a weak base in lysosomes and compromises autophagosome fusion with lysosomes and autophagosome degradation in the final stage of autophagy[20]. Light microscopy showed that the viability of HCT116 p53⁻/⁻ cells treated with the combination of 3-MA or CQ and 5-FU was significantly lower than that of controls (Figure 3a), with more detached and shrunken cells appearing. Similar results were obtained in HT-29 cells, indicating that autophagy plays a protective role and facilitates the chemoresistance of the treated cells. Next, we suppressed the expression of Atg 5 and Beclin 1, two key regulators of autophagy,

with short interfering RNA (siRNA). Cells were seeded at equal densities in six-well plates and transfected with siRNA. Twenty-four hours after the addition of siRNA, HCT116 p53⁻/⁻ and HT-29 cells were treated with 5-FU for 24 h. As shown in Fig. 3b, the expression level of Atg 5 or Beclin 1 was significantly down-regulated, together with the accumulation of p62 in siRNA-transfected groups, revealing that Atg 5 or Beclin 1 siRNA block 5-FU-induced autophagy at an early stage. The MTT assay was used to assess cytotoxicity in 5-FU-treated HCT116 p53⁻/⁻ and HT-29 cells transfected with control siRNA or anti-Atg5 or Beclin1 siRNAs. Knockdown of Atg5 or Beclin1 augmented the cytotoxicity of 5-FU (Figure 3c). A colony formation assay showed that knockdown of Atg5 or Beclin1 suppressed the colony formation efficiency (Figure 3d). To obtain objective quantification of apoptosis, we performed an Annexin V–FITC dual staining assay followed by flow cytometry. In agreement with above results, the dual staining assay also showed that the percentage of apoptotic cells was significantly higher in HCT116 p53⁻/⁻ and HT-29 cells treated with the combination of 3-MA and 5-FU than that in their respective controls (Figure 3e).

For further confirmation, both HCT116 p53⁻/⁻ and HT-29 cells were first incubated with an antibody against LC3, a key component of the autophagosomal membrane, not required for the initiation of autophagy but which instead mediates phagophore expansion and autophagosome formation[21]. When autophagy is induced, punctate fluorescence of LC3B can be observed. As shown in Fig. 3f, punctate fluorescence was very frequently observed in HCT116 p53⁻/⁻ and HT-29 cells treated with 5-FU alone. However, after treatment with

Figure 3 | Blockade of autophagy enhances 5-FU-induced cell death in HCT116 p53$^{-/-}$ and HT29 cells. (A) Pharmacological inhibition of autophagy with 3-MA or CQ. Representative cell morphological changes are detected by light microscopy; characteristic morphological features of apoptosis were observed, including detachment and cell shrinkage. (B) The expression of ATG5 or Beclin1 in HCT116 p53$^{-/-}$ and HT29 cells transiently transfected with negative control siRNA, siAtg5 or siBeclin1 were determined by western blotting. (C) Cell viability was quantified by the MTT assay in HCT116 p53$^{-/-}$ and HT29 cells transiently transfected with negative control siRNA, siAtg5 or siBeclin1, *p < 0.05, compared with the 5-FU group. The experiments were performed in triplicate. (D) Clonogenic survival assay, *p < 0.05, compared with the 5-FU group. The experiments were performed in triplicate. (E) Representative results of annexin V-FITC/PI staining and quantitative analysis; values are expressed as the mean ± SD of three independent experiments; *p < 0.05, compared with the 5-FU group. The experiments were performed in triplicate. (F) HCT116 p53$^{-/-}$ and HT29 cells were treated by 20 µM 5-FU with or without 3-MA for 24 h. Cells were fluorescently labeled and imaged using a confocal microscope. Green, FITC-labeled LC3; Blue, DAPI-labeled nucleus; quantitative analyses of punctate fluorescence numbers are shown; *p < 0.05, compared with the 5-FU group. The experiments were performed in triplicate. (G) The expression of LC3B II and active caspase-3 was examined by western blotting.

the combination of 3-MA and 5-FU, this fluorescence was effectively inhibited. This finding suggests that 3-MA can efficiently inhibit autophagy induced by 5-FU. We next performed western blotting analysis to detect cleaved LC3-II and active caspase-3 (Figure 3g). A significantly increased LC3-II/I ratio was shown in HCT116 p53$^{-/-}$ and HT29 cells after 5-FU treatment. Importantly, more prominent active caspase-3 was observed in HCT116 p53$^{-/-}$ and HT-29 cells when these cells were treated with the combination of 3-MA and 5-FU. In conclusion, induction of autophagy has emerged as a drug resistance mechanism that promotes the survival of p53-deficient and mutant p53-expressing colon cancer cells in response to 5-FU, and inhibition of autophagy enhances the cytotoxic effect of 5-FU in these resistant cells.

5-FU induces JNK activation and Bcl-2 phosphorylation in HCT116 p53$^{-/-}$ and HT29 cells. JNK has been demonstrated to contribute to autophagic induction in response to genotoxic stress[22,23]. To investigate whether JNK activation is a key determinant for the up-regulation of LC3 during 5-FU-induced autophagy in p53-deficient and mutant p53-expressing colon cancer cells, the

abundance of MAPKs and phosphorylated forms of these proteins were assessed by western blotting using specific antibodies in HCT116 p53$^{+/+}$, HCT116 p53$^{-/-}$, RKO and HT-29 cells treated with various concentrations of 5-FU for 24 h. We found that JNK was activated in a dose-dependent manner in 5-FU-treated HCT116 p53$^{-/-}$ cells compared with HCT116 p53$^{+/+}$ cells. Similar results were obtained in HT-29 cells but not in RKO cells (Figure 4a), indicating that JNK may be activated in HCT116 p53$^{-/-}$ and HT-29 cells after 5-FU treatment. For further confirmation, the abundance of c-Jun, phospho-c-Jun and phospho-Bcl-2 was assessed by western blotting. Our data showed that, following 5-FU treatment, c-Jun and Bcl-2 phosphorylation was significantly increased in HCT116 p53$^{-/-}$ and HT-29 cells (Figure 4b). Moreover, an increase in the LC3-II/I ratio and induced p62 degradation were observed when HCT116 p53$^{-/-}$ and HT-29 cells were treated with 5-FU. Because JNK-mediated Bcl-2 phosphorylation has been previously reported to regulate genotoxic stress-induced autophagy[22], we analyzed whether JNK activation and Bcl-2 phosphorylation may be associated with the induction of autophagy in HCT116 p53$^{-/-}$ and HT-29 cells in response to 5-FU.

4

Figure 4 | 5-FU induces JNK activation and Bcl-2 phosphorylation in HCT116 p53$^{-/-}$ and HT-29 cells. (A) HCT116 p53$^{-/-}$ and HT29 cells were treated with varying concentrations of 5-FU for 24 h. The expression of several key MAPK regulators was examined by western blot (the blots were cropped, and the full-length blots are included in the supplementary information). (B) HCT116 p53$^{-/-}$ and HT29 cells were treated by 5-FU for 24 h, and then JNK, c-Jun and Bcl-2 phosphorylation, as well as the expression of active caspase-3 and several key autophagic regulators, were analyzed by western blotting.

Inhibition of JNK activity sensitizes HCT116 p53$^{-/-}$ and HT-29 cells to 5-FU-mediated cell death. Recent reports have shown that JNK-dependent phosphorylation of Bcl-2 can lead to autophagy activation and/or cell survival[20]. To further evaluate the relationship between 5-FU-induced autophagy and JNK signaling, we specifically attenuated JNK activation using a pharmacological inhibitor of JNK SP600125 (10 μM). Inhibition of JNK by SP600125 decreased LC3B punctate fluorescence (Figure 5a). Western blot confirmed that the blockage of JNK significantly decreased the LC3-II/I ratio and phosphorylation of JNK, c-Jun and Bcl-2, but increased the abundance of cleaved caspase-3 and p62 (Figure 5b). This result suggests that 5-FU-mediated JNK activation probably promotes autophagy as a pro-survival effect by inducing Bcl-2 phosphorylation, and inhibition of JNK increases the cytotoxic effect of 5-FU in HCT116 p53$^{-/-}$ and HT-29 cells. Cell viability and colony formation assays also showed the same results (Figure 5c, d).

Next, we used short interfering RNA (siRNA) to knockdown JNK expression in HCT116 p53$^{-/-}$ and HT-29 cells and tested the effect of such inhibition on the sensitivity to 5-FU. Both HCT116 p53$^{-/-}$ and HT-29 cells were transfected with JNK-specific siRNA. Decreased expression of JNK was confirmed by RT–PCR (Figure 5e). As shown in Fig. 5f, silencing JNK in HCT116 p53$^{-/-}$ and HT-29 cells significantly blocked LC3-II induction and inhibited the phosphorylation

of c-Jun and Bcl-2. Moreover, inhibition of autophagy by JNK knockdown increased 5-FU-induced apoptosis as shown in Fig. 5f and g. Taken together, these data demonstrate that JNK signaling is a critical mediator of the 5-FU resistance associated with increased autophagy, and JNK inhibition re-sensitized HCT116 p53$^{-/-}$ and HT-29 cells to 5-FU, resulting in more apoptosis.

Discussion

In this study, we demonstrate that protective autophagy is involved in the 5-FU resistance of p53-deficient or mutant p53-expressing colon cancer cells and that 5-FU-mediated JNK activation in HCT116 p53$^{-/-}$ and HT-29 cells promotes autophagy as a pro-survival effect, probably by inducing Bcl-2 phosphorylation. Finally, JNK inhibition augments the cytotoxic effect of 5-FU in these resistant cells.

It is increasingly appreciated that autophagy supports cancer cell survival because of certain selective advantages in response to chemotherapy or radiation therapy, although on the other hand, autophagy can also contribute to cancer cell death in some cases[24,25]. Autophagy inhibitors may potentiate the anti-cancer effect of 5-FU via cell cycle suppression[26]. Li et al. showed that inhibition of autophagy augmented the effects of 5-FU in *in vitro* and *in vivo* human colon cancer models[27]. Moreover, autophagy inhibition was also proven to promote 5-FU-induced apoptosis by stimulating ROS

5

Figure 5 | JNK inhibition augments the cytotoxic effect of 5-FU in HCT116 p53$^{-/-}$ and HT29 cells by reducing survival autophagy. (A) HCT116 p53$^{-/-}$ and HT29 cells were treated with 5-FU with or without SP600125 for 24 h. Cells were fluorescently labeled and imaged using a confocal microscope. Green, FITC-labeled LC3; Blue, DAPI-labeled nucleus; quantitative analyses of punctate fluorescence numbers are shown; *p < 0.05, compared with the 5-FU group. The experiments were performed in triplicate. (B) JNK, c-Jun and Bcl-2 phosphorylation, as well as the expression of active caspase-3 and several key autophagic regulators, were analyzed in HCT116 p53$^{-/-}$ and HT29 cells treated with the combination of 5-FU and SP600125 (the blots were cropped, and the full-length blots are included in the supplementary information). (C) Cell viability was quantified by the MTT assay in these resistant cells treated with the combination of 5-FU and SP600125; *p < 0.05, compared with the 5-FU group. The experiments were performed in triplicate. (D) Clonogenic survival assay; *p < 0.05, compared with the 5-FU group. The experiments were performed in triplicate. (E) The expression of JNK in HCT116 p53$^{-/-}$ and HT29 cells was analyzed by RT-PCR when these cells were transiently transfected with the negative control siRNA siJNK (F) JNK, c-Jun and Bcl-2 phosphorylation, as well as the expression of active caspase-3 and several key autophagic regulators, were analyzed in HCT116 p53$^{-/-}$ and HT29 cells transiently transfected with the negative control siRNA siJNK (the blots were cropped, and the full-length blots are included in the supplementary information). (G) Cell viability was quantified by the MTT assay in these resistant cells transiently transfected with the negative control siRNA siJNK; *p < 0.05, compared with the 5-FU group. The experiments were performed in triplicate.

formation in human non-small cell lung cancer A549 cells[28]. Here we confirm the same finding by showing that aberrant autophagosome accumulation is involved in the 5-FU resistance of p53-deficient and mutant p53-expressing colon cancer cells; conversely, autophagy inhibition sensitizes these resistant cells to 5-FU. The latter finding indicates that autophagy plays a protective role and facilitates p53-deficient and mutant p53-expressing colon cancer cells resistance to 5-FU. Therefore autophagy inhibitors could be used to develop a promising therapeutic strategy to enhance the effects of chemotherapy and improve clinical outcomes for colon cancer patients with a p53 mutation.

The JNK pathway plays a critical role in cell proliferation, apoptosis, motility, metabolism and DNA repair. In response to genotoxic stress, JNK also contributes to autophagic induction. JNK1-mediated multisite phosphorylation of Bcl-2 stimulates starvation-induced autophagy by disrupting the Bcl-2/Beclin 1 complex[29]. The transcrip-

tion factor c-Jun, a prototypic JNK target, protects against sustained hepatic endoplasmic reticulum stress, thereby promoting hepatocyte survival by inducing macroautophagy[30]. JNK inhibition has been previously reported to be associated with a resistant phenotype to various genotoxic stimuli, such as chemotherapeutic drugs[31,32]. However, our data indicate that in HCT116 p53$^{-/-}$ and HT-29 cells, JNK can induce autophagy, leading to the promotion of colon cancer cell survival in response to 5-FU. We showed, for the first time, that JNK inhibition did not generate a chemoresistant phenotype but enhanced the cytotoxic effect of 5-FU in these resistant cells. Similarly, Paillas et al. reported that MAPK14/p38α conferred irinotecan resistance to TP53-defective cells by inducing survival autophagy[33]. O'Donovan et al. showed that the induction of autophagy by drug-resistant esophageal cancer cells promotes their survival and recovery following treatment with chemotherapeutics[34]. High-mobility group box 1 protein (HMGB1) rendered myeloid leukemia

cells resistant to conventional anticancer treatments through increasing JNK-dependent autophagy[14]. In addition, recent studies have indicated a considerable overlap or interdependence of apoptosis and autophagy mediated by p38MAPK signaling; however, whether JNK may also control the balance between apoptosis and autophagy remains unresolved[35–37]. Moreover, the role of autophagy and JNK in cancer treatment is unclear because JNK activity might vary according to cell type, the stress signal and other circumstances. Therefore, analyzing the role of JNK in regulating the balance of 5-FU-induced apoptosis and autophagy will be a key issue. In the present study, we demonstrated that 5-FU-mediated JNK activation promotes autophagy as a pro-survival effect probably by inducing Bcl-2 phosphorylation, and inhibition of JNK increases the cytotoxic effect of 5-FU in HCT116 p53$^{-/-}$ and HT-29 cells.

In conclusion, our report indicates that increased autophagy may be an important mechanism to enable p53-deficient or mutant p53-expressing colon cancer cells to acquire resistance to 5-FU, and JNK activation triggers autophagy as a pro-survival effect to protect cancer cells against the cytotoxic effects of 5-FU, probably via inducing Bcl-2 phosphorylation.

Methods

Cell lines and reagents. The human colorectal carcinoma HCT116 p53$^{+/+}$, HCT116 p53$^{-/-}$ cell lines were kindly given by Mian Wu. HT-29 and RKO cells were purchased from ATCC (LGC Standards SLU, Barcelona, Spain). The cell lines were maintained in McCoy's 5A or Dulbecco's modified Eagle's medium (DMEM; Gibco BRL, Rockville, MD, USA) with 10% fetal bovine serum (FBS), 100 units/mL penicillin, 100 μg/mL streptomycin (Invitrogen), and 2 mmol/L L-glutamine at 37°C in a humidified atmosphere of 95% air and 5% CO$_2$. 5-FU was purchased from Jinyao Amino Acid Co., Ltd. (Tianjin, China). 3-MA and CQ were obtained from Sigma–Aldrich.

Measurement of Cell Viability and Apoptosis. Cell viability was determined by MTT assay. Cells were seeded in 96-well flat bottom microtiter plates at a density of 1 × 10⁴ cells per well. 24 h later, 5-FU was added at the concentrations indicated for 24 h. The absorbance was measured on a microplate reader (Synergy HT, Bio-Tek, USA) at 570 nm. Phartmingen annexin V-FITC Apoptosis Detection Kit I (BD, USA) was used to detect apoptosis and the estimation procedure was performed according to the manufacturer's instructions. 2 × 10⁶ cells were seeded into a 6 cm dish. After attachment overnight, cells were washed twice with PBS and the medium was replaced medium with 30 μg/ml 5-FU for 24 h. All cells including the floating cells in the culture medium were harvested. The cells were resuspended in ice-cold 1 × binding buffer at a concentration of 1 × 10⁶ cells/ml. 100 μl of cell suspension were each mixed with 5 μl FITC Annexin V and 5 μl PI. The mixture was incubated for 15 min at room temperature in the dark and then analyzed by FACScalibur Flow Cytometer (BD Biosystems, Heidelberg, Germany).

Clonogenic survival assay. Cells were trypsinized and plated in triplicate into six well plates at different densities based on cell types. Cells were treated with the indicated concentrations of 5-FU or vehicle control for 24 h. Twenty-four hours after 5-FU treatment, the medium was removed and cells were maintained in normal culturing medium. Two weeks after the cells were plated, they were washed and stained with crystal violet, and the colonies containing ≥50 cells were counted.

Semi-quantitative RT–PCR. Semi-quantitative RT–PCR was performed as described before[18]. The GAPDH mRNA sequence was also amplified as an internal control.

Immunofluorescent confocal laser microscopy for LC3 and lysosome co-location. Lysosome was firstly labeled by incubation with Lyso Tracker (Invitrogen, L7528), a lysosomal reporter dye, for 90 min at 37°C. Cells were collected, fixed and permeabilized with 1% CHAPS buffer (150 mM NaCl, 10 mM HEPES, 1.0% CHAPS) at room temperature for 10 min, incubated with anti-LC3 for 2 h at room temperature, and washed with PBS, incubated for another 45 min.

Western Blot Analysis. Cells were harvested from cultured dishes and were lysed in a lysis buffer [20 mM Tris-HCl pH 7.6, 1 mM EDTA, 140 mM NaCl, 1% NP-40, 1% aprotinin, 1 mM phenylemethylsulfonyl fluoride (PMSF), 1 mM sodium vanadate]. Protein concentration was determined using a BCA Protein Assay Kit (Pierce). Cell lysates (40 μg protein/line) were separated on a 5 to 20% Tris-Tricine Ready Gel SDS-PAGE (Bio-Rad) for nitrocellulose membrane blotting. The blotted membranes were blocked with 5% skim milk for 1 h and were incubated with primary antibodies. The immunoreactive bands were visualized by enhanced chemiluminescence using horseradish perox-idase-conjugated IgG secondary antibodies. Band density was measured by densitometry, quantified using gel plotting macros of NIH image 1.62, and normalized to an indicated sample in the identical membrane.

RNA interference. Cells were transfected with either nonspecific siRNA (Qiagen,1027280), Atg5 siRNA (Qiagen, SI02655310), Beclin1 siRNA (Cell Signaling Technology, #6222) or JNK siRNA (Cell Signaling Technology, #6233) via LipofectAMINE RNAi max (Invitrogen, 13778150) according to the manufacturer's instructions.

Electron microscopy. Treated cells were washed and fixed for 30 min in 2.5% glutaraldehyde. The samples were treated with 1.5% osmium tetroxide, dehydrated with acetone and embedded in Durcupan resin. Thin sections were poststained with lead citrate andexamined in the TECNAI 10 electron microscope (Philips, Holland) at 60 kV.

Statistical analyses. Results are expressed as values of mean ± standard deviation (SD). Statistical analysis was performed using SPSS 11.0 for Windows (SPSS Inc., Chicago, IL, USA). We performed paired t-test (two-tailed) statistical analysis, statistical significance was set at p<0.05.

1. Karpiński, P., Sasiadek, M. M. & Blin, N. Aberrant epigenetic patterns in the etiology of gastrointestinal cancers. *J Appl Genet* **49**, 1–10 (2008).
2. Herszényi, L. & Tulassay, Z. Epidemiology of gastrointestinal and liver tumors. *Eur Rev Med Pharmacol Sci* **14**, 249–258 (2010).
3. Sun, X. X., Dai, M. S. & Lu, H. 5-fluorouracil activation of p53 involves an MDM2-ribosomal protein interaction. *J Biol Chem* **282**, 8052–8059 (2007).
4. Subbarayan, P. R. *et al.* Chronic exposure colorectal cancer cells in culture to fluoropyrimidine analogs induces thymidylate synthase and suppresses p53. A molecular explanation for the mechanism of 5-FU resistance. *Anticancer Res* **30**, 1149–1156 (2010).
5. Huang, C. *et al.* The combination of 5-fluorouracil plus p53 pathway restoration is associated with depletion of p53-deficient or mutant p53-expressing putative colon cancer stem cells. *Cancer Biol Ther* **8**, 2186–2193 (2009).
6. Sui, X. *et al.* p53 signaling and autophagy in cancer: A revolutionary strategy could be developed for cancer treatment. *Autophagy* **7**, 565–571 (2011).
7. Altman, B. J. & Rathmell, J. C. Autophagy: not good OR bad, but good AND bad. *Autophagy* **5**, 569–570 (2009).
8. Lum, J. J., DeBerardinis, R. J. & Thompson, C. B. Autophagy in metazoans: cell survival in the land of plenty. *Nat Rev Mol Cell Biol* **6**, 439–448 (2005).
9. Mizushima, N., Levine, B., Cuervo, A. M. & Klionsky, D. J. Autophagy fights disease through cellular self-digestion. *Nature* **451**, 1069–1075 (2008).
10. Kondo, Y., Kanzawa, T., Sawaya, R. & Kondo, S. The role of autophagy in cancer development and response to therapy. *Nat Rev Cancer* **5**, 726–734 (2005).
11. Chen, N. & Debnath, J. Autophagy and tumorigenesis. *FEBS Lett* **584**, 1427–1435 (2010).
12. Høyer-Hansen, M. & Jäättelä, M. Autophagy: An emerging target for cancer therapy. *Autophagy* **4**, 574–580 (2008).
13. Kelkel, M. *et al.* ROS-independent JNK activation and multisite phosphorylation of Bcl-2 link diallyl tetrasulfide-induced mitotic arrest to apoptosis. *Carcinogenesis* **33**, 2162–2171 (2012).
14. Zhao, M. *et al.* HMGB1 regulates autophagy through increasing transcriptional activities of JNK and ERK in human myeloid leukemia cells. *BMB Rep* **44**, 601–066 (2011).
15. Sau, A. *et al.* Targeting GSTP1-1 induces JNK activation and leads to apoptosis in cisplatin-sensitive and -resistant human osteosarcoma cell lines. *Mol Biosyst* **8**, 994–1006 (2012).
16. Li, Y. *et al.* Gene silencing of FANCF potentiates the sensitivity to mitoxantrone through activation of JNK and p38 signal pathways in breast cancer cells. *PLoS One* **7**, e44254 (2012).
17. Zhu, B. *et al.* Cross-talk of alpha tocopherol-associated protein and JNK controls the oxidative stress-induced apoptosis in prostate cancer cells. *Int J Cancer* **132**, 2270–2282 (2013).
18. Song, X., Kim, S. Y. & Lee, Y. J. The role of Bcl-xL in synergistic induction of apoptosis by mapatumumab and oxaliplatin in combination with hyperthermia on human colon cancer. *Mol Cancer Res* **10**, 1567–1579 (2012).
19. Klionsky, D. J. *et al.* Guidelines for the use and interpretation of assays for monitoring autophagy. *Autophagy* **8**, 445–544 (2012).
20. Nilsson, J. R. Does chloroquine, an antimalarial drug, affect autophagy in Tetrahymena pyriformis? *J Protozool* **39**, 9–16 (1992).
21. Sui, X. *et al.* Autophagy and Chemotherapy Resistance: A Promising Therapeutic Strategy for Cancer. *Cell Death Dis* **4**, e838 (2013).
22. Notte, A., Ninane, N., Arnould, T. & Michiels, C. Hypoxia counteracts taxol-induced apoptosis in MDA-MB-231 breast cancer cells: role of autophagy and JNK activation. *Cell Death Dis* **4**, e638 (2013).
23. Sun, T. *et al.* c-Jun NH2-terminal kinase activation is essential for up-regulation of LC3 during ceramide-induced autophagy in human nasopharyngeal carcinoma cells. *J Transl Med* **9**, 161 (2011).
24. Brech, A., Ahlquist, T., Lothe, R. A. & Stenmark, H. Autophagy in tumour suppression and promotion. *Mol Oncol* **3**, 366–375 (2009).
25. Chen, S. *et al.* Autophagy is a therapeutic target in anticancer drug resistance. *Biochim Biophys Acta* **1806**, 220–229 (2010).
26. Choi, J. H., Yoon, J. S., Won, Y. W., Park, B. B. & Lee, Y. Y. Chloroquine enhances the chemotherapeutic activity of 5-fluorouracil in a colon cancer cell line via cell cycle alteration. *APMIS* **120**, 597–604 (2012).

27. Li, J., Hou, N., Faried, A., Tsutsumi, S. & Kuwano, H. Inhibition of autophagy augments 5-fluorouracil chemotherapy in humancolon cancer in vitro and in vivo model. *Eur J Cancer* **46**, 1900–1909 (2010).

28. Pan, X. *et al.* Autophagy inhibition promotes 5-fluorouraci-induced apoptosis by stimulating ROS formation in human non-small cell lung cancer A549 cells. *PLoS One* **8**, e56679 (2013).

29. Wei, Y. *et al.* JNK1-mediated phosphorylation of Bcl-2 regulates starvation-induced autophagy. *Mol Cell* **30**, 678–688 (2008).

30. Fuest, M. *et al.* The transcription factor c-Jun protects against sustained hepatic endoplasmic reticulum stress thereby promoting hepatocyte survival. *Hepatology* **55**, 408–418 (2012).

31. Mansouri, A. *et al.* Sustained activation of JNK/p38 MAPK pathways in response to cisplatin leads to Fas ligand induction and cell death in ovarian carcinoma cells. *J Biol Chem* **278**, 19245–1956 (2003).

32. Xiao, F., Liu, B. & Zhu, Q. X. c-Jun N-terminal kinase is required for thermotherapy-induced apoptosis in human gastric cancer cells. *World J Gastroenterol* **18**, 7348–7356 (2012).

33. Paillas, S. *et al.* MAPK14/p38α confers irinotecan resistance to TP53-defective cells by inducing survival autophagy. *Autophagy* **8**, 1098–1112 (2012).

34. O'Donovan, T. R., O'Sullivan, G. C. & McKenna, S. L. Induction of autophagy by drug-resistant esophageal cancer cells promotes their survival and recovery following treatment with chemotherapeutics. *Autophagy* **7**, 509–524 (2011).

35. de la Cruz-Morcillo, M. A. *et al.* P38MAPK is a major determinant of the balance between apoptosis and autophagy triggered by 5-fluorouracil: implication in resistance. *Oncogene* **31**, 1073–1085 (2012).

36. Sui, X. *et al.* p38 and JNK MAPK pathways control the balance of apoptosis and autophagy in response to chemotherapeutic agents. *Cancer lett* **344**, 174–179 (2014).

37. Chaanine, A. H. *et al.* JNK modulates FOXO3a for the expression of the mitochondrial death and mitophagy marker BNIP3 in pathological hypertrophy and in heart failure. *Cell Death Dis* **3**, 265 (2012).

38. Hu, X. *et al.* Protocadherin 17 acts as a tumor suppressor inducing tumor cell apoptosis and autophagy, and is frequently methylated in gastric and colorectal cancers. *J Pathol* **229**, 62–73 (2011).

Acknowledgments

Author contributions

H.P. and W.H. designed the study. X.S. wrote the main manuscript text. X.S., N.K., X.W., Y.F., X.H., Y.X., W.C., K.W., D.L., W.J., F.L., Y.Z., H.H., L.G. and X.Z. performed experiments. Y.X. and W.C. prepared figures. H.H. and L.G. did the statistical analyses. All authors reviewed the manuscript.

Additional information

Supplementary information accompanies this paper at http://www.nature./scientificreports

Competing financial interests: The authors declare no competing financial interests.

How to cite this article: Sui, X.B. *et al.* JNK confers 5-fluorouracil resistance in p53-deficient and mutant p53-expressing colon cancer cells by inducing survival autophagy. *Sci. Rep.* **4**, 4694; DOI:10.1038/srep04694 (2014).